Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;27(8):691-692.
doi: 10.1111/iju.14269. Epub 2020 May 31.

Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?

Hiroki Ishihara  1 , Toshio Takagi  1 , Tsunenori Kondo  2 , Hironori Fukuda  1 , Kazuhiko Yoshida  1 , Kazunari Tanabe  1
Affiliations

Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?

Hiroki Ishihara et al. Int J Urol. 2020 Aug.
No abstract available

PubMed Disclaimer

References

    1. Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int. Immunopharmacol. 2018; 58: 125-35.
    1. Escudier B, Motzer RJ, Sharma P et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur. Urol. 2017; 72: 368-76.
    1. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012; 366: 883-92.
    1. Puza CJ, Bressler ES, Terando AM et al. The emerging role of surgery for patients with advanced melanoma treated with immunotherapy. J. Surg. Res. 2019; 236: 209-15.
    1. Flippot R, Dalban C, Laguerre B et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J. Clin. Oncol. 2019; 37: 2008-16.

MeSH terms

LinkOut - more resources